Lineage Cell Therapeutics, Inc. (LCTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2.5M 5M 7.5M Q3 '24: 3.8M Q4 '24: 2.9M Q1 '25: 1.5M Q2 '25: 2.8M Q3 '25: 3.7M Q4 '25: 6.6M Q1 '26: 1.7M Q2 '26: 1.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 2M 4M 6M Q1 '22: 5.1M Q2 '22: 4.3M Q3 '22: 2.8M Q4 '22: 1.8M Q1 '23: 2.3M Q2 '23: 3.1M Q3 '23: 1.1M Q4 '23: 1.8M Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '24: -3.8M Q4 '24: -5.1M Q1 '25: -6.5M Q2 '25: -19.8M Q3 '25: -3.8M Q4 '25: -6.5M Q1 '26: -7.6M Q2 '26: -8.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -3M Q4 '24: -3.3M Q1 '25: -4.1M Q2 '25: -30.5M Q3 '25: -29.8M Q4 '25: 851K Q1 '26: -4.8M Q2 '26: 1.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 90K 180K 270K Q2 '23: 127K Q3 '23: 169K Q4 '23: 256K Q1 '24: 98K Q2 '24: 44K Q3 '24: 38K Q4 '24: 154K Q1 '25: 36K Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '24: -5.8M Q4 '24: -6.3M Q1 '25: -4.9M Q2 '25: -5.5M Q3 '25: -3.6M Q4 '25: -4.9M Q1 '26: -8.1M Q2 '26: -7.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '24: -5.9M Q4 '24: -6.7M Q1 '25: -5M Q2 '25: -5.6M Q3 '25: -3.6M Q4 '25: -5.3M Q1 '26: -8.1M Q2 '26: -7.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q1 '24: 182.9M Q2 '24: 188.8M Q3 '24: 188.8M Q1 '25: 226.1M Q2 '25: 228.4M Q3 '25: 228.9M Q1 '26: 261.2M Q2 '26: 261.5M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.30 -0.20 -0.10 0.00 0.10 0.20 0.30 Q2 '24: -0.14 Q3 '24: -0.12 Q4 '24: -0.10 Q1 '25: -0.08 Q2 '25: -0.18 Q3 '25: -0.29 Q4 '25: -0.28 Q1 '26: -0.29 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.